2021 annual financial data
Halozyme Therapeutics 2021 Operating margin
Halozyme Therapeutics 2021 operating margin with verified reported values.
Direct answer
Operating margin was 62.24%.
Operating income was 275,902,000 USD and net income was 402,710,000 USD.
Operating cash flow was 299,440,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 443,310,000 USD
- Operating income
- 275,902,000 USD
- Net income
- 402,710,000 USD
- Operating cash flow
- 299,440,000 USD